saying that Juno “made misleading omissions regarding a patient death in the Phase 2 Rocket trial of its lead product candidate, JCAR015 … Juno knew the patient death was important and ...

On July 12, the US Food and Drug Administration (FDA) reinstated Juno Therapeutics' ROCKET phase 2 clinical trial of CAR-T cell therapy (JCAR015) for acute lymphocytic leukemia (ALL), just days ...